Effects of Calorie Restriction and Cold Stimuli on Health-related Indicators, Cognitive and Motor Functions

December 28, 2022 updated by: Lithuanian Sports University

Effects of 2-day and 6-day Calorie Restriction and Whole-body Cooling Strategies on Health-related Indicators, Cognitive and Motor Functions

The goal of this clinical trial was to identify if duration of acute calorie restriction (CR)/fasting or combination CR with cold stimuli have any effects on mental and physical health-related markers, and to clarify if different fasting strategies have any effect on cognitive and motor functioning efficiency in different genders.

The main questions it aims to answer were:

  • Does fasting duration have any effect on fasting evoked responses?
  • Does cold interventions can modulate fasting evoked responses?
  • Does sex have any effect on acute fasting evoked responses?

For the first part, participants were randomly classified into 4 groups: two experimental groups: 2-days of CR (0 kcal diet) and 6-days of CR (0 kcal diet), and two control groups: 2-days or 6-days usual diet. For the second part, participants were randomly assigned to undergo the following conditions: 2-days of CR with two 10-min whole-body cold-water immersions on separate days, 2-days of CR without cold-water immersion, 2-days without CR with two 10-min whole-body cold-water immersions on separate days, or 2-days of the usual diet without cold-water immersion in a randomized crossover fashion. Changes in anthropometric characteristics, perceived stress, metabolism, overall health (total blood count, sex hormones, etc.), psycho-emotional state, cognitive and motor functions were examined.

Study Overview

Detailed Description

The goal of this clinical trial was to identify if duration of acute calorie restriction (CR)/fasting or combination CR with cold stimuli have any effects on mental and physical health-related markers, and to clarify if different fasting strategies have any effect on cognitive and motor functioning efficiency in different genders.

At first study part, participants were randomly classified into 4 groups: two experimental groups: 2-days of calorie restriction (CR) (0 kcal diet) and 6-days of CR (0 kcal diet), and two control groups: 2-days or 6-days usual diet. In the experimental groups, the participants were instructed to follow a prescribed zero-calorie diet with water provided ad libitum over a period of 2 or 6 days. In the control groups, the participants were instructed to maintain their previous eating habits for 2 or 6 days. Body weight and composition, heart rate variability, pulmonary gas exchange, blood pressure, and body temperature were assessed. Subsequently, participants completed self-assessment questionnaires, and then saliva samples were collected for further cortisol and sex hormones analysis, also capillary and venous blood samples were taken for ketone, glucose, insulin, lipid profile, catecholamines, brain-derived neurotrophic factor, glucagon, interleukin-10, metabolites of the kynurenines pathway and complete blood count concentrations evaluation. Then, the manual dexterity, and the cognitive and neuromuscular functions were assessed. The same measurements were repeated before each trial, after each trial and after 1 week.

At second part, participants were randomly assigned to undergo the following conditions: 2-days of CR with two 10-min whole-body cold-water immersions on separate days, 2-days of CR without cold-water immersion, 2-days without CR with two 10-min whole-body cold-water immersions on separate days, or 2-days of the usual diet without cold-water immersion in a randomized crossover fashion. The same measurements described in first part were repeated before each and after each condition.

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kaunas, Lithuania
        • Lithuanian Sports University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  • body mass index 19.5-29.9 kg/m2,
  • age 18-40 years,
  • no excessive regular moderate or vigorous physical activity, i.e., ≥3 times per week,
  • non-smokers,
  • no medications that could affect the results of experiment,
  • no history of any eating, oncological, metabolic, cardiovascular, skeletal, neuromuscular, pulmonary disorders or diseases, mental disabilities or conditions that could be worsened by exposure to acute cold (14°) water or fasting and affect experimental variables,
  • no history of alcoholism or dependence on psychotropic drugs,
  • no blood/needle phobia,
  • no involvement in any temperature-manipulation program or extreme temperature exposure for ⩾3 months,

Exclusion criteria: smoking, were in a weight-reduction program, followed a low-carbohydrate diet.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 2-days of calorie restriction with whole body cooling

Healthy young subjects participated in a 2-day CR (0 kcal with water provided ad libitum ) with two 10-min whole body cooling practices on separate days.

All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data.

The 2-days (48 hours) of zero-calorie restricted diet (with water provided ad libitum) with two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min.
Experimental: 6-days of calorie restriction

Healthy young subjects participated in 6-day CR (0 kcal with water provided ad libitum).

All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data.

The 6-days (144 hours) of prescribed zero-calorie prescribed diet with water provided ad libitum.
No Intervention: 2-days of the usual diet (control)

During the control trial, the healthy young subjects were instructed to maintain their previous eating habits for 2 days.

All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data.

No Intervention: 6 days of the usual diet (control)

During the control trial, the healthy young subjects were instructed to maintain their previous eating habits for 6 days.

All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data.

Experimental: 2-days of calorie restriction without whole-body cooling

Healthy young subjects participated in a 2-day CR (0 kcal with water provided ad libitum ) without whole body cooling.

All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months; do not use any medications that could affect experimental data.

2 days (48 hours) of prescribed zero-calorie diet with water provided ad libitum .
Active Comparator: 2-days of usual diet with whole-body cooling

Healthy young subjects participated two 10-min whole body cooling practices on separate days and were instructed to maintain their previous eating habits for 6 days.

All participants were asked to not perform excessive sports activities while the research was ongoing, not to be involved in any temperature-manipulation program or extreme temperature exposure for ⩾3 months, CR programmes; do not use any medications that could affect experimental data.

Two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min. During intervention, participants were instructed to maintain their previous eating habits.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in body mass and body composition (kg)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Body mass and composition (in kg) was evaluated using Tanita Body Composition Analyzer (Japan).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in body mass index (kg/m2)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The body mass index (in kg/m2) was defined as the body mass divided by the square of the body height.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in substrate oxidation
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Oxygen consumption and carbon dioxide output every 5 s on a breath-by breath basis using an Oxycon Mobile spirometry system (Oxygen Mobile, Jaeger/ VIASYS Healthcare, Germany) was measured at rest, and the respiratory quotient (RQ=VCO2/VO2) was computed to determine substrate utilisation. The RQ values for fat was assumed as 0.7, for protein was assumed as 0.8 and for carbohydrate was assumed as 1.0.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in energy expenditure (kcal/day)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Resting energy expenditure (REE) using Weir equation modified Weir equation: REE (kcal/day)=[3.941(oxygen consumption) + 1.106(carbon dioxide output)] x 1440
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in body temperature (°C)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Rectal temperature (°C) was measured using a thermocouple (Rectal Probe, Ellab, Denmark) inserted to a depth of 12 cm past the anal sphincter, skin temperature (°C) was measured with thermistors (Skin/Surface Probe, DM852, Ellab) at three sites: back, thigh, and forearm, and right lateral gastrocnemius muscle temperature (°C) was measured using a needle microprobe (MKA; Ellab).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in heart rate variability (ms)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
R-R intervals (in ms) in supine resting conditions were recorded using a Polar HR sensor (Finland) and and simultaneously transferred to Polar Pro Trainer 5 software (Finland).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in heart rate variability (time domain) (ms)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Heart rate variability data were analyzed using Kubios HR Variability Analysis software (Finland). In the time domain that reflects general heart rate variability (HRV), the standard deviation of normal-to-normal intervals (SDNN; estimate of overall HRV) and the root mean square of successive differences (RMSSD; estimate of short-term components of HRV) were assessed (in ms).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in heart rate variability (time domain) (Ln)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Heart rate variability data were analyzed using Kubios HR Variability Analysis software (Finland). In the time domain that reflects general heart rate variability (HRV), the standard deviation of normal-to-normal intervals (SDNN; estimate of overall HRV) and the root mean square of successive differences (RMSSD; estimate of short-term components of HRV) were assessed and logarithmically transformed (Ln) to correct the skewness of distribution.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in heart rate variability (frequency domain) (ms2)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Heart rate variability data were analyzed using Kubios HR Variability Analysis software (Finland). In the frequency domain that measures the more specific contribution of the autonomic nervous system branch, we used the fast Fourier transform to assess low-frequency (LF; estimates sympathetic and parasympathetic activity) and high-frequency (HF; estimates parasympathetic activity) powers in absolute units (in ms2).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in heart rate variability (frequency domain) (Ln)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Heart rate variability data were analyzed using Kubios HR Variability Analysis software (Finland). In the frequency domain that measures the more specific contribution of the autonomic nervous system branch, we used the fast Fourier transform to assess low-frequency (LF; estimates sympathetic and parasympathetic activity) and high-frequency (HF; estimates parasympathetic activity) powers were assessed and logarithmically transformed (Ln) to correct the skewness of distribution.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in heart rate variability (frequency domain) (nu)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Heart rate variability data were analyzed using Kubios HR Variability Analysis software (Finland). In the frequency domain that measures the more specific contribution of the autonomic nervous system branch, we used the fast Fourier transform to assess low-frequency (LF; estimates sympathetic and parasympathetic activity) and high-frequency (HF; estimates parasympathetic activity) powers in normalized units (in nu).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in heart rate (bpm)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Heart rate (in bpm) was recorded using a heart rate sensor with a chest strap (Polar, Finland) in laying position at rest.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in blood pressure (mmHg)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Resting systolic and diastolic blood pressure (in mmHg) was measured using a digital electronic blood pressure monitor (Microlife, Switzerland)
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in perceived stress
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Perceived stress was evaluated with visual analog scales (VAS) ranging from 0 ("no stress") to 100 ("the highest stress imaginable").according to how participants feel "right now".
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in appetite sensations
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Appetite sensations (hunger and fullness) were evaluated with VAS ranging from 0 ("I am not hungry at all/not at all full") to 100 ("I have never been more hungry/totally full") according to how participants feel "right now".
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in mood state
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Mood state was evaluated with Brunel mood scale according to how participants feel "right now". The scale consists of 24 items divided into six subscales: anger, confusion, depression, fatigue, tension, and vigor. The items are answered on a 5-point scale, and each subscale, with four relevant items, are summed to produce a raw score in the range of 0-16, where a higher score indicates greater endorsement of the specific mood state.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in venous complete blood count (10^9/L)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Venous complete blood count with 5 different white blood count (WBC) components (absolute neutrophils, lymphocytes, monocytes, eosinophils, basophils) analysis (in 10^9/L) was performed using an automated Mythic 60 hematology analyzer (Switzerland).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in venous complete blood count (%)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Venous complete blood count with 5 different white blood count (WBC) components (absolute neutrophils, lymphocytes, monocytes, eosinophils, basophils) analysis (in %) was performed using an automated Mythic 60 hematology analyzer (Switzerland).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in serum female sex hormones concentration (pg/mL)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The venous serum 17beta-estradiol and progesterone (in pg/mL) were measured using enzyme-linked immunosorbent assay kits and a Spark multimode microplate reader (Tecan, Austria).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in serum female sex hormones concentration (mIU/ml)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The venous serum follicle stimulating and luteinizing hormones (in mIU/ml) were measured using enzyme-linked immunosorbent assay kits and a Spark multimode microplate reader (Tecan, Austria).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in serum brain-derived neurotrophic factor concentration (pg/ml)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The venous serum brain-derived neurotrophic factor (in pg/ml) was measured using enzyme-linked immunosorbent assay kits (Cat.No. DBD00; R&D Systems, Emeryville, USA) and a Spark multimode microplate reader (Tecan, Austria).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in serum interleukin-10 concentration (pg/ml)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The venous serum interleukin (in pg/ml) was measured using enzyme-linked immunosorbent assay kits (Cat. No. 30147233; IBL International GmBH, Germany) and a Spark multimode microplate reader (Tecan, Austria).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in serum insulin concentration (μIU/ml)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The venous serum insulin concentrations (in μIU/ml) were measured using enzyme-linked immunosorbent assay kits (Cat. No. E-EL-H2237, Elabscience, China) and a Spark multimode microplate reader (Tecan, Austria).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in serum glucagon concentration (pg/ml)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The venous serum glucagon concentrations (in pg/ml) were measured using enzyme-linked immunosorbent assay kits (DIAsource ImmunoAssays S.A.,Belgium) and a Spark multimode microplate reader (Tecan, Austria).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in plasma catecholamines concentration (ng/ml)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The venous plasma adrenaline and noradrenaline concentrations (in ng/ml) were measured using enzyme-linked immunosorbent assay kits (Cat. No. RE59242, IBL International GmbH, Germany) and a Spark multimode microplate reader (Tecan, Austria).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in venous glucose concentration (mmol/l)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The venous glucose concentration (in mmol/l) was measured in venous blood samples using a Glucocard X-mini plus glucose analyser (Arkray, Japan).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in insulin sensitivity
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
An oral glucose insulin sensitivity [OGIS] index derived from an oral glucose tolerance test was calculated.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in plasma metabolites of the kynurenine pathway (μm)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
An ultra-performance liquid chromatography-tandem mass spectrometry system (UPLC-MS/MS) to measure venous plasma levels of tryptophan, kynurenine, kynurenic acid, 3-hydroxy-kynurenine, quinolinic acid, nicotinamide and picolinic acid (in μm). The UPLC-MS/MS system used a Xevo TQ-XS triple quadrupole mass spectrometer (Waters) with a Z-spray electrospray interface, and the system was operated in electrospray positive multiple reaction monitoring mode.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in salivary cortisol concentration (µg/dl)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The saliva samples were collected to measure cortisol level (in µg/dl) using a enzyme-linked immunosorbent assay (ELISA) kits and a Spark multimode microplate reader (Tecan, Austria).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in salivary testosterone concentration (µg/dl)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The saliva samples were collected to measure testosterone level (in µg/dl) using a enzyme-linked immunosorbent assay (ELISA) kits and a Spark multimode microplate reader (Tecan, Austria).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in capillary lipid profile (mmol/l)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The capillary blood samples were collected from finger to measure lipid profile (in mmol/l) (total cholesterol, high density and low density cholesterol, triglycerides) using a CardioChek PA analyzer (USA).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in manual dexterity performance (sec)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The Grooved Pegboard was used to evaluate the ability to coordinate the fingers and manipulate objects promptly in time twice (in sec).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in information processing (μV)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Using a 32-channel Standard Brain Cap (EasyCap GmbH, Germany), event-related potentials (ERPs) during oddball tasks by two modalities (auditory and visual) were recorded. Peak amplitudes (μV) of the N1, N2 and P3 at three sites (Fz, Cz, and Pz) were defined.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in information processing (ms)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Using a 32-channel Standard Brain Cap (EasyCap GmbH, Germany), event-related potentials (ERPs) during oddball tasks by two modalities (auditory and visual) were recorded. Latencies (ms) of the N1, N2 and P3 at three sites (Fz, Cz, and Pz) were defined.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in brain neural network activity (µV2)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Resting electroencephalography was recorded using a 32-channel Standard Brain Cap (EasyCap GmbH, Germany). Participant's data were averaged across the epochs for Fz, Cz and Pz electrodes, and mean absolute power (in µV2) was computed for theta (4-8 Hz), alpha (8-12 Hz) and beta (12-30 Hz) frequency band.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in cognitive performance (ms)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Two oddball tasks were used in this study: in one task, visual stimuli were presented, and in the other task, auditory stimuli were presented. Reaction times (in ms) were measured.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in cognitive performance (%)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Two oddball tasks were used in this study: in one task, visual stimuli were presented, and in the other task, auditory stimuli were presented. Accuracy of response to the target stimulus (in %) were measured.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in reflexes (mV)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Soleus H-reflexes, V-waves and M-waves were evoked by 0.5 ms square-wave pulses using a high-voltage stimulator (Digitimer, UK). The amplitudes (in mV) of the electrical evoked reflexes were evaluated.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in reflexes (ms)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Soleus H-reflexes, V-waves and M-waves were evoked by 0.5 ms square-wave pulses using a high-voltage stimulator (Digitimer, UK). The latencies (in ms) of the electrical evoked reflexes were evaluated.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in muscle activity (mV)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Tibial muscles electromyographic (EMG) amplitude (in mV) parameters of muscular activity were measured using surface EMG (Biometrics, UK) thorough neuromuscular function assessment.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in muscle activity (Hz)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Tibial muscles electromyographic (EMG) frequency (in Hz) parameters of muscular activity were measured using surface EMG (Biometrics, UK) thorough neuromuscular function assessment.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in voluntary torque (Nm)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Isometric and isokinetic voluntary torques (in Nm) of the ankle plantar flexion/dorsiflexion muscles were measured using an isokinetic dynamometer (Biodex Medical Systems, USA).
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in involuntary torque (Nm)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Involuntary torque of the ankle plantar flexion muscles were measured using an isokinetic dynamometer (Biodex Medical Systems, USA) and a high-voltage stimulator (Digitimer DS7A, Digitimer, UK). Peak torques (in Nm) induced by electrical stimulation at 20 Hz,at 100 Hz, and at TT100 were measured.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in muscle contraction and relaxation (ms)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The contraction and half-relaxation time (in ms) were measured in resting TT100 contractions.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in central activation ratio (%)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
To evaluate central activation ratio (CAR), a TT-100 Hz stimuli was superimposed on the maximal voluntary contraction (MVC), and the CAR was computed using the following equation: CAR = MVC/(MVC+TT-100 Hz) × 100%, where where a CAR of 100% indicates complete activation of the exercising muscle and a CAR < 100% indicates central activation failure or inhibition.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in reactive strength
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The drop jump test on a force mobile platform (AccuPower, AMTI, USA) was used to evaluate reactive-strength. Jumps were performed while holding the hands of the subject on the hips were requested jump as fast as possible after the drop off from the platform and make sure that the jump is the highest possible. Reactive strength index as jump height / time to take off was calculated.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in jump performance (cm)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The drop jump test on a force mobile platform (AccuPower, AMTI, USA) was used to evaluate jump performance. Jumps were performed while holding the hands of the subject on the hips were requested jump as fast as possible after the drop off from the platform and make sure that the jump is the highest possible. Jump height (in cm) height was evaluated.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in jump performance (m/s)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
The drop jump test on a force mobile platform (AccuPower, AMTI, USA) was used to evaluate jump performance. Jumps were performed while holding the hands of the subject on the hips were requested jump as fast as possible after the drop off from the platform and make sure that the jump is the highest possible. Time to take off (in m/s) was evaluated.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in height (m)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Height (in m) was measured using a Harpenden anthropometer set (Holtain Ltd, UK)
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in skinfold thickness (mm)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Skinfolds thickness (in mm) was measured using a skinfold caliper (Saehan, Korea) at 7 sites: chest, midaxilla, triceps, subscapular, abdominal, suprailiac and thigh.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in body fatness (%)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
7-Site Skinfold Jackson & Pollock protocol was used to estimate body fat (in %) based on measurements of subcutaneous fat. As presented earlier, skinfolds were measured at 7 sites, and further body fatness was calculated as 495/(1.112-(0.00043499*s(sum of 7 skinfolds)+(0.00000055*s*s)-(0.00028826*a(age)))-450 for males and 495/(1.097-(0.00046971*s)+(0.00000056*s*s)-(0.00012828*a))-450 for females.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in physical activity (Step count)
Time Frame: 3 days before condition, during 48 or 144 hours of interventions and during 1 week post-condition. (2 weeks)
Garmin activity tracker estimated the step count.
3 days before condition, during 48 or 144 hours of interventions and during 1 week post-condition. (2 weeks)
Change in sleep (h)
Time Frame: 3 days before condition, during 48 or 144 hours of interventions and during 1 week post-condition. (2 weeks)]
Sleep statistics including total hours of sleep and the time spent in different sleep stages were assessed with Garmin activity tracker.
3 days before condition, during 48 or 144 hours of interventions and during 1 week post-condition. (2 weeks)]
Change in oxygen consumption and carbon dioxide output (ml/min)
Time Frame: Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Oxygen consumption and carbon dioxide output (in ml/min) every 5 s on a breath-by breath basis using an Oxycon Mobile spirometry system (Oxygen Mobile, Jaeger/ VIASYS Healthcare, Germany) was measured at rest.
Pre-condition, 48 or 144 hours post-condition, and 1 week after recovery
Change in capillary blood ketone concentrations (mmol/l)
Time Frame: Pre-condition, 24, 48 or 144 hours post-condition, and 1 week after recovery
The capillary blood ketone concentration (in mmol/l) was assessed using an Abbott FreeStyle Optium Neo H blood glucose and ketone monitoring system (Australia) using blood obtained from a finger-prick sample.
Pre-condition, 24, 48 or 144 hours post-condition, and 1 week after recovery
Change in capillary blood glucose concentrations (mmol/L)
Time Frame: Pre-condition, 24, 48 or 144 hours post-condition, and 1 week after recovery
The capillary blood glucose concentration (in mmol/L) was assessed using an Abbott FreeStyle Optium Neo H blood glucose and ketone monitoring system (Australia) using blood obtained from a finger-prick sample.
Pre-condition, 24, 48 or 144 hours post-condition, and 1 week after recovery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Katerina Židonienė, Lithuanian Sports University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 8, 2021

Primary Completion (Actual)

September 5, 2022

Study Completion (Actual)

October 5, 2022

Study Registration Dates

First Submitted

September 9, 2022

First Submitted That Met QC Criteria

September 15, 2022

First Posted (Actual)

September 19, 2022

Study Record Updates

Last Update Posted (Estimate)

December 29, 2022

Last Update Submitted That Met QC Criteria

December 28, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fasting

Clinical Trials on 2-days of zero calorie restriction and whole-body cold-water immersion

3
Subscribe